Literature DB >> 24530939

Tumoral stem cell reprogramming as a driver of cancer: Theory, biological models, implications in cancer therapy.

Carolina Vicente-Dueñas1, Julia Hauer2, Lucía Ruiz-Roca1, Deborah Ingenhag2, Alba Rodríguez-Meira1, Franziska Auer2, Arndt Borkhardt3, Isidro Sánchez-García4.   

Abstract

Cancer is a clonal malignant disease originated in a single cell and characterized by the accumulation of partially differentiated cells that are phenotypically reminiscent of normal stages of differentiation. According to current models, therapeutic strategies that block oncogene activity are likely to selectively target tumor cells. However, recent evidences have revealed that cancer stem cells could arise through a tumor stem cell reprogramming mechanism, suggesting that genetic lesions that initiate the cancer process might be dispensable for tumor progression and maintenance. This review addresses the impact of these results toward a better understanding of cancer development and proposes new approaches to treat cancer in the future.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer stem cell; Mouse model; Oncogenes; Stem cells; Tumoral reprogramming

Mesh:

Year:  2014        PMID: 24530939     DOI: 10.1016/j.semcancer.2014.02.001

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  10 in total

1.  A preliminary study of the role of extracellular -5'- nucleotidase in breast cancer stem cells and epithelial-mesenchymal transition.

Authors:  Jiangang Yu; Xiaohong Liao; Luying Li; Lei Lv; Xiuling Zhi; Jerry Yu; Ping Zhou
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-09-26       Impact factor: 2.416

Review 2.  Metabostemness: a new cancer hallmark.

Authors:  Javier A Menendez; Tomás Alarcón
Journal:  Front Oncol       Date:  2014-09-29       Impact factor: 6.244

Review 3.  Could Vitamin D Analogues Be Used to Target Leukemia Stem Cells?

Authors:  Idoia García-Ramírez; Alberto Martín-Lorenzo; Inés González-Herrero; Guillermo Rodriguez-Hernández; Carolina Vicente-Dueñas; Isidro Sánchez-García
Journal:  Int J Mol Sci       Date:  2016-06-06       Impact factor: 5.923

Review 4.  The Making of Leukemia.

Authors:  Inés González-Herrero; Guillermo Rodríguez-Hernández; Andrea Luengas-Martínez; Marta Isidro-Hernández; Rafael Jiménez; Maria Begoña García-Cenador; Francisco Javier García-Criado; Isidro Sánchez-García; Carolina Vicente-Dueñas
Journal:  Int J Mol Sci       Date:  2018-05-17       Impact factor: 5.923

5.  A Novel Function for KLF4 in Modulating the De-differentiation of EpCAM-/CD133- nonStem Cells into EpCAM+/CD133+ Liver Cancer Stem Cells in HCC Cell Line HuH7.

Authors:  Zeynep Firtina Karagonlar; Soheil Akbari; Mustafa Karabicici; Eren Sahin; Sanem Tercan Avci; Nevin Ersoy; Kıvılcım Eren Ates; Tugsan Balli; Bilge Karacicek; Kubra Nur Kaplan; Canan Celiker; Nese Atabey; Esra Erdal
Journal:  Cells       Date:  2020-05-12       Impact factor: 6.600

6.  Regulation of Sox2 and stemness by nicotine and electronic-cigarettes in non-small cell lung cancer.

Authors:  Courtney M Schaal; Namrata Bora-Singhal; Durairaj Mohan Kumar; Srikumar P Chellappan
Journal:  Mol Cancer       Date:  2018-10-15       Impact factor: 27.401

Review 7.  Modeling Hematological Diseases and Cancer With Patient-Specific Induced Pluripotent Stem Cells.

Authors:  Huensuk Kim; Christoph Schaniel
Journal:  Front Immunol       Date:  2018-09-28       Impact factor: 7.561

Review 8.  Group phenotypic composition in cancer.

Authors:  Jean-Pascal Capp; James DeGregori; Aurora M Nedelcu; Beata Ujvari; Andriy Marusyk; Robert Gatenby; Frédéric Thomas; Antoine M Dujon; Justine Boutry; Pascal Pujol; Catherine Alix-Panabières; Rodrigo Hamede; Benjamin Roche
Journal:  Elife       Date:  2021-03-30       Impact factor: 8.140

Review 9.  Is lineage decision-making restricted during tumoral reprograming of haematopoietic stem cells?

Authors:  Geoffrey Brown; Isidro Sanchez-Garcia
Journal:  Oncotarget       Date:  2015-12-22

10.  CD133 expression may be useful as a prognostic indicator in colorectal cancer, a tool for optimizing therapy and supportive evidence for the cancer stem cell hypothesis: a meta-analysis.

Authors:  Yang Zhao; Jing Peng; Enlong Zhang; Ning Jiang; Jiang Li; Qi Zhang; Xuening Zhang; Yuanjie Niu
Journal:  Oncotarget       Date:  2016-03-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.